Design and synthesis of doublecortin-like kinase 1 inhibitors and their bioactivity evaluation
Authors:
Open Access
- 7 December 2023
- journal article
- research article
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 39 (1) , 2287990
Abstract
Doublecortin-like kinase 1 (DCLK) is a microtubule-associated serine/threonine kinase that is upregulated in a wide range of cancers and is believed to be related to tumour growth and development. Upregulated DCLK1 has been used to identify patients at high risk of cancer progression and tumours with chemotherapy-resistance. Moreover, DCLK1 has been identified as a cancer stem cell (CSC) biomarker in various cancers, which has received considerable attention recently. Herein, a series of DCLK1 inhibitors were prepared based on the previously reported XMD8-92 structure. Among all the synthesised compounds, D1, D2, D6, D7, D8, D12, D14, and D15 showed higher DCLK1 inhibitory activities (IC50 40-74 nM) than XMD8-92 (IC50 161 nM). Compounds D1 and D2 were selective DCLK1 inhibitors as they showed a rather weak inhibitory effect on LRRK2. The antiproliferative activities of these compounds were also preliminarily evaluated. The structure-activity relationship revealed by our compounds provides useful guidance for the further development of DCLK1 inhibitors.Keywords
Funding Information
- National Natural Science Foundation of China (81872738, 81772565)
- National Key R&D Program of China (2022YFF1203005, 2022YFC2303700)
This publication has 26 references indexed in Scilit:
- Biochemical and Structural Insights into Doublecortin-like Kinase Domain 1Structure, 2016
- Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K-δ/γ InhibitorsACS Medicinal Chemistry Letters, 2016
- Cancer stem cells: a challenging paradigm for designing targeted drug therapiesDrug Discovery Today, 2015
- DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinomaOncotarget, 2014
- XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanismCancer Letters, 2014
- DCAMKL-1 Regulates Epithelial–Mesenchymal Transition in Human Pancreatic Cells through a miR-200a–Dependent MechanismCancer Research, 2011
- Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2Nature Chemical Biology, 2011
- Cancer Stem Cells: A New Theory Regarding a Timeless DiseaseChemical Reviews, 2009
- Roots and stems: stem cells in cancerNature Medicine, 2006
- Reaction of Functionalized Anilines with Dimethyl Carbonate over NaY Faujasite. 3. Chemoselectivity toward Mono-N-methylationThe Journal of Organic Chemistry, 2003